Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

EPAD

- PMLiVE

Brain training ‘could cut dementia risk’, says study

Findings suggest computerised speed of processing training can reduce cognitive decline by 48 percent

- PMLiVE

Alzheimer’s: the numbers we cannot forget

In this article, Consultant David Cooney explores the success rate of trials in AD and the reasons for this incredulous situation, as well as looking at the some of the...

Blue Latitude Health

- PMLiVE

Industry welcomes European diagnostics regulations

Trade bodies say they will support greater use of personalised medicines

- PMLiVE

European pharma considering medicine pricing shakeup

EFPIA will later this month discuss proposals for a value-based pricing system

- PMLiVE

Leveraging HCP transparency insights to drive future customer investments

EFPIA’s disclosure requirements present an opportunity to assess strategy and effectiveness

AstraZeneca AZ

AZ gets $100m from Lilly as Alzheimer’s drug progresses

BACE inhibitor candidate displays ‘encouraging’ positive safety data

- PMLiVE

Researchers say ‘neurostatins’ may ward off Alzheimer’s

Preclinical studies show bexarotene prevents nerve cell degeneration

- PMLiVE

MHP wins EFPIA account for EU health outcomes campaign

The UK agency will be supported by its Brussels partner cabinetDN

EU flag

EMA unveils draft guidelines for Alzheimer’s disease research

Puts plans for evaluating potential new therapies out for consultation

Biogen Idec building

Biogen buys into Rodin’s Alzheimer’s candidate

And may acquire the epigenetics-focused Massachusetts firm

EU flag

Public-private partnerships ‘making a difference’ in Europe

One of those is the IMI, which has helped drug development bottlenecks

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links